Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Mens Novo Nordisk tjener milliarder på fedmemedicin, bliver medicinalgigantens amerikanske medarbejderes pension investeret i junkfood Mens Novo Nordisk tjener styrtende på vægttabsmedicin ...